PILA PHARMA AB
SSTO:PILA1.50
SEK
-0.07
(-4.78%)
ISIN
SE0015988274
Return %
Stock
S&P 500
1Y
-31.74
14.39
3Y
11.74
81.42
5Y
-76.96
68.62
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Semi-annual Revenue
SEK
•
in mil. unless spec.Semi-annual Earnings Per Share
SEK
•
in mil. unless spec.Semi-annual Dividends Per Share
SEK
•
in mil. unless spec.Company Description
- CEO
- Gustav Hanghøj Gram
- Full Time Employees
- 1
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Norra Vallgatan 72 Malmö SN Sweden 211 22
- IPO Date
- Jul 15, 2021
- Website
- pilapharma.com
- Similar Companies
- Business
- Pila Pharma AB (publ) is a Swedish clinical-stage biotech company headquartered in Malmö, Sweden, specializing in the development of novel oral drugs based on TRPV1 inhibition for the treatment of obesity, type 2 diabetes, and diseases with an inflammatory background. The company’s main product candidate is XEN-D0501, a TRPV1 antagonist currently in phase 2a clinical trials, which has demonstrated a favorable safety profile and significant effects on enhancing endogenous insulin response and reducing cardiovascular biomarkers in people with obesity and type 2 diabetes. Pila Pharma's portfolio also includes research projects targeting erythromelalgia, for which XEN-D0501 holds orphan drug designation, and abdominal aorta aneurysm, validated by recent preclinical proof-of-concept data showing significant reduction of aneurysm growth in mice. The company’s product pipeline targets oral therapeutic options that differ mechanistically from GLP-1 based treatments, aiming to provide an alternative with potentially improved side effect profiles and broader patient access. In the last 1-2 years, Pila Pharma has made strategic advances including an oversubscribed rights issue in 2025 that raised nearly SEK 30 million to fund dedicated obesity studies and preclinical rat studies. The company entered a research collaboration with Uppsala University and contracted Gubra, a Danish preclinical CRO, to conduct preclinical trials of XEN-D0501 in obesity. These moves emphasize Pila Pharma’s strategic shift to focus on oral obesity treatment with plans for subsequent human clinical trials following positive preclinical results. Insider ownership has increased, and management signals strong commitment to advancing proof-of-concept data that could position Pila Pharma as a differentiated player in a growing obesity drug market, addressing patient subgroups inadequately served by current injectable therapies. Founded in 2014, Pila Pharma operates primarily in the pharmaceutical and biotech segments, with a clinical development focus on endocrinology, obesity, diabetes, and rare inflammatory diseases. The company holds patents related to TRPV1 antagonists for obesity and diabetes treatment and continues to file additional patents covering synthesis, formulation, and use of XEN-D0501 and backup compounds. Pila Pharma’s approach combines innovative small molecule oral therapies with ongoing commitments to strategic partnerships, funding, and clinical development within Sweden and international preclinical research networks. The company remains pre-revenue, advancing its pipeline toward potential commercialization and out-licensing opportunities. Pila Pharma AB’s main business activities center on the discovery, development, and clinical testing of oral anti-diabetic and anti-obesity agents, including proprietary TRPV1 inhibitor technology, preclinical studies for cardiovascular and aneurysm conditions, and drug development for rare diseases with inflammatory components. Its core products include the clinical-stage drug candidate XEN-D0501 alongside complementary drug candidates in preclinical and early development phases. The company’s recent strategic funding and collaborations significantly bolster its capabilities and prospects in addressing unmet medical needs in metabolic and inflammatory disorders through oral treatment modalities.